Definium Therapeutics, Inc. - 8-K Filing
Definium Therapeutics announced the first patient was dosed in its Phase 3 Ascend study evaluating DT120 Orally Disintegrating Tablet (ODT) for major depressive disorder. The trial is expected to enroll 175 participants and will measure changes from baseline on the Montgomery-Åsberg Depression Rating Scale at Week 6 between DT120 ODT 100 µg and placebo. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $MNMD